SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 16th, 2021 • Enochian Biosciences Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 14, 2021, between Enochian Biosciences Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 27th, 2023 • Enochian Biosciences Inc • Pharmaceutical preparations
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 20, 2023, is made by and between ENOCHIAN BIOSCIENCES INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
PURCHASE AGREEMENTPurchase Agreement • June 27th, 2023 • Enochian Biosciences Inc • Pharmaceutical preparations • Illinois
THIS PURCHASE AGREEMENT (the “Agreement”), dated as of June 20, 2023, is made by and between ENOCHIAN BIOSCIENCES INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 14th, 2020 • Enochian Biosciences Inc • Pharmaceutical preparations • Illinois
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), July 8, 2020, by and between ENOCHIAN BIOSCIENCES, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
STRICTLY CONFIDENTIAL Enochian BioSciences, Inc. Century City Medical PlazaExclusive Agency Agreement • June 16th, 2021 • Enochian Biosciences Inc • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • August 14th, 2014 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations • New York
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • August 12th, 2011 • Putnam Hills Corp. • Delaware
AGREEMENT entered into as of the 18thday of January, 2011, by and between Putnam Hills Corp., a Delaware corporation with an address at c/o Sunrise Securities, 641 Lexington Avenue, 25th Floor, New York, NY 10022 (the “Company”) and Nathan A. Low, an individual with an address c/o Sunrise Securities, 641 Lexington Avenue, 25th Floor, New York, NY 10022 (the “Purchaser”).
COMMON STOCK PURCHASE WARRANT Renovaro inc.Common Stock Purchase Warrant • June 21st, 2024 • Renovaro Inc. • Pharmaceutical preparations • Delaware
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, [●] (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time after the Issue Date (the “Initial Exercise Date”) and on or prior to the close of business on the Termination Date (as defined below) but not thereafter, to subscribe for and purchase from Renovaro Inc., a Delaware corporation (the “Company”), of up to [●] shares (subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock, par value $0.0001 per share (“Common Stock”).
FORM OF COMMON STOCK PURCHASE WARRANT enochian biosciences inc.Warrant Agreement • August 7th, 2023 • Renovaro Biosciences Inc. • Pharmaceutical preparations • Delaware
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received [●] (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time after the Issue Date (the “Initial Exercise Date”) and on or prior to the close of business on the Termination Date (as defined below) but not thereafter, to subscribe for and purchase from Enochian Biosciences Inc., a Delaware corporation (the “Company”), of up to [●] shares (subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock, par value $0.0001 per share (“Common Stock”).
SUBSCRIPTION AGREEMENTSubscription Agreement • February 23rd, 2018 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations • Delaware
This SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is made by and between DanDrit Biotech USA, Inc. a Delaware corporation (the “Company”), and the undersigned (“Subscriber”) as of the date this Subscription Agreement is accepted by the Company, as set forth on the Company’s signature page hereto.
MASTER SERVICES AGREEMENTMaster Services Agreement • February 14th, 2014 • DanDrit Biotech USA, Inc. • Blank checks • England
This Master Services Agreement (the “Agreement”) is made and entered into on 11th October, 2011, (the “Effective Date”), by and between DanDrit Biotech A/S, a Danish corporation, with offices at Høffdingsvej 34, 2500 Valby, Denmark (hereinafter referred to as “Client”) and Aptiv Solutions (UK) Ltd, together with its Affiliates, with offices at Hemel One, Boundary Way, Hemel Hempstead, Hertfordshire, HP2 (hereinafter referred to as “Aptiv Solutions”), both hereinafter referred as a “Party” or collectively as the “Parties”.
FORM OF SUBSCRIPTION AGREEMENTSubscription Agreement • October 10th, 2023 • Renovaro Biosciences Inc. • Pharmaceutical preparations • Delaware
This SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is made by and between Renovaro BioSciences Inc., a Delaware corporation (the “Company”), and the other signatories listed on the signature pages hereto (each, a “Subscriber”, and collectively, the “Subscribers”) as of October __, 2023.
THIS WARRANT AND THE SHARES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. EXCEPT AS OTHERWISE SET FORTH HEREIN NEITHER THIS WARRANT NOR ANY OF SUCH SHARES MAY BE SOLD, TRANSFERRED OR...Warrant Agreement • February 9th, 2018 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations • Delaware
THIS Common Stock Purchase Warrant CERTIFIES THAT, for value received, ____________ or his registered assigns (“Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 PM Eastern Standard Time on December 31, 2019 (the “Expiration Date”) but not thereafter, to subscribe for and purchase from DanDrit Biotech USA, Inc., a Delaware corporation with offices at Stumpedyssevej 17, 2970 Hørsholm, Denmark (the “Company”) an aggregate of up to 300,000 shares of common stock, par value $0.0001 per share, of the Company (the “Shares”), at an initial price per Share of $2.00, as adjusted in accordance with Section 2 below (the “Purchase Price”).
SELLER REGISTRATION RIGHTS AGREEMENTSeller Registration Rights Agreement • February 14th, 2024 • Renovaro Inc. • Pharmaceutical preparations • Delaware
THIS SELLER REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of February 13, 2024 (the “Execution Date”), by and among Renovaro Biosciences Inc., a Delaware corporation (together with its successors, the “Purchaser”), and the undersigned parties listed as “Investors” on the signature page hereto (the “Investors” and each an “Investor”).
Subscription AgreementSubscription Agreement • July 3rd, 2014 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations • New York
The undersigned (the “Investor”) hereby confirms and agrees with DanDrit Biotech USA, Inc., a Delaware corporation (the “Company”), as follows:
SUBSCRIPTION AGREEMENTSubscription Agreement • February 23rd, 2018 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations • Delaware
This SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is made by and between DanDrit Biotech USA, Inc. a Delaware corporation (the “Company”), and the undersigned (“Subscriber”) as of the date this Subscription Agreement is accepted by the Company, as set forth on the Company’s signature page hereto.
CONSULTING AGREEMENTConsulting Agreement • May 15th, 2018 • Enochian Biosciences Inc • Pharmaceutical preparations • Florida
This CONSULTING AGREEMENT (this “Agreement”) is made and entered into as of February 16, 2018 (the “Effective Date”), by and among Dandrit Biotech USA, Inc. (the “Company”), its wholly owned subsidiary, Enochian Biopharma, Inc. (“Enochian) and Carl Sandler, an individual (the “Consultant”).
BUSINESS LEASE AGREEMENT SUBLESSOR: Paseco ApS, Danish CVR No 31 36 36 08 LESSEE: Dandrit Biotech, A/S, Danish CVR No 26 02 73 22 PREMISES: Bredgade 75, 3rd floor, DK-1263 Copenhagen KBusiness Lease Agreement • March 31st, 2014 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations
The premises are to be used for offices and may not, without the written consent of the Sublessor, be used for any other purpose.
CFO Service AgreementCfo Service Agreement • September 29th, 2017 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations
DanDrit Biotech A/S CVR No 26 02 73 22 c/o Symbion Science Park Fruebjergvej 3 2100 Copenhagen Denmark (hereinafter referred to as the ”Company”)
SUBSCRIPTION AGREEMENTSubscription Agreement • June 21st, 2024 • Renovaro Inc. • Pharmaceutical preparations • Delaware
This SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is made by and between Renovaro Inc., a Delaware corporation (the “Company”), and [●] (the “Subscriber”) as of June 14, 2024.
AGREEMENT AND PLAN OF SHARE EXCHANGEShare Exchange Agreement • February 14th, 2014 • DanDrit Biotech USA, Inc. • Blank checks • Delaware
This AGREEMENT AND PLAN OF SHARE EXCHANGE (this “Agreement”) is entered into as of this 12th day of February, 2014 by and among Putnam Hills Corp., a Delaware corporation (“Putnam”), Dandrit BioTech A/S, a Danish company (“Dandrit”) and Niels Erik Nielsen (the “Shareholders’ Representative”), the representative of shareholders a majority of the issued and outstanding capital stock of Dandrit (collectively, the “Dandrit Consenting Shareholders” and together will all other holders of the outstanding capital stock of Dandrit, each a “Dandrit Shareholder”, and collectively, the “Dandrit Shareholders”). Each of the parties to this Agreement is individually referred to herein as a “Party” and collectively as the “Parties”.
SUBSCRIPTION AGREEMENTSubscription Agreement • March 24th, 2021 • Enochian Biosciences Inc • Pharmaceutical preparations • Florida
This SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is made by and between Enochian BioSciences Inc., a Delaware corporation (the “Company”), and the other signatories listed on the signature pages hereto (each, a “Subscriber”, and collectively, the “Subscribers”) as of March ____, 2021.
CFO SERVICE AGREEMENT between DanDrit Biotech A/S CVR No 26 02 73 22 c/o Symbion Science Park Fruebjergvej 3 (hereinafter referred to as the "Company") and Robert E. Wolfe PO Box 189 Randolph, VT 05060 (hereinafter referred to as the "CFO")Cfo Service Agreement • June 23rd, 2014 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations
EMPLOYMENT AGREEMENTEmployment Agreement • November 14th, 2024 • Renovaro Inc. • Pharmaceutical preparations • Delaware
This EMPLOYMENT AGREEMENT (this “Agreement”), dated as of October 14, 2024, by and between DAVID WEINSTEIN, residing at 23277 Water Circle, Boca Raton, Florida 33486 (the “Senior Executive”), and RENOVARO, INC., a Delaware corporation with its mailing address located at 2080 Century Park East, 906, Los Angeles, CA 90067 (the “Company”).
FORM OF STANDSTILL AND LOCK-UP AGREEMENTStandstill and Lock-Up Agreement • January 17th, 2018 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations
This Standstill and Lock-Up Agreement (this “Agreement”) is made and entered into as of [●], 2018 (the “Effective Date”), by and among DanDrit Biotech USA, Inc., a Delaware corporation (“Parent”), Weird Science, LLC, a California limited liability company (the “Majority Stockholder”) and RS Group ApS, a Danish limited company and a stockholder of Parent (“RS Group” and together with Majority Stockholder, the “Stockholders” and each, a “Stockholder”). Parent, Majority Stockholder and RS Group are each referred to as a “Party” or collectively as the “Parties.”
AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTEConvertible Promissory Note • February 9th, 2018 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations
This Amendment No. 1 to Convertible Promissory Note (this “Amendment”), dated as of _________, 2017 (the “Effective Date”), is entered into by and between DanDrit Biotech USA, Inc., a Delaware corporation (the “Company”), and ___________ (the “Holder”).
DEBT INSTRUMENT was concluded on this day between Sune Olsen Holding ApS Jagtvej 169B, 3rd floor DK-2100 Copenhagen Ø Danish CVR No 25372727 of the first part (hereinafter referred to as the “Creditor”) and Dandrit Biotech A/S Symbion Sciencepark,...Debt Instrument • February 14th, 2014 • DanDrit Biotech USA, Inc. • Blank checks
Place: Copenhagen Ø Place: Copenhagen Ø Date: March 31, 2013 Date: March 31, 2013 As the Debtor: As the Creditor: /s/ Eric Leire, CEO, DanDrit Biotech A/S /s/ Sune Olsen, President, Sune Olsen Holding ApS
STATEMENT OF WORK AND LICENSE AGREEMENT for Influenza and Coronavirus IndicationsStatement of Work and License Agreement • April 22nd, 2021 • Enochian Biosciences Inc • Pharmaceutical preparations • California
This Statement of Work and License Agreement for Influenza and Coronavirus Indications effective as of April 18, 2021 (the “Effective Date”), is made by and among G TECH BIO, LLC, a California limited liability company (“Licensor”), ENOCHIAN BIOSCIENCES, INC., a Delaware corporation (“Licensee”) and G HEALTH RESEARCH FOUNDATION, a not-for-profit entity organized under the laws of the state of California doing business as Seraph Research Institute (“SRI” and, together with Licensor, the “Research Parties;” and Licensee, SRI and Licensor, collectively the “Parties” and each, a “Party”).
EARLY ACCESS AGREEMENTEarly Access Agreement • February 14th, 2014 • DanDrit Biotech USA, Inc. • Blank checks
This exclusive Early Access Agreement (“Agreement”) is made and entered into the 20th day of December 2013 (“Effective Date”) by and between
FORM OF INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • January 17th, 2018 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations
This Investor Rights Agreement (this “Agreement”) is made and entered into as of [●], 2018 (the “Effective Date”), by and among DanDrit Biotech USA, Inc., a Delaware corporation (“Parent”), Weird Science, LLC, a California limited liability company (“Majority Stockholder”) and RS Group ApS, a Danish limited company and a stockholder of Parent (“RS Group” and together with Majority Stockholder, the “Stockholders”). Parent and each Stockholder are each referred to as a “Party” or collectively as the “Parties.”
Contact: For Immediate ReleaseCollaboration Agreement • September 30th, 2014 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations
AMENDMENT NO. 3 TO PROMISSORY NOTEPromissory Note • February 23rd, 2023 • Enochian Biosciences Inc • Pharmaceutical preparations
This Amendment No. 3 to Promissory Note (this “Amendment”), dated as of December 30, 2022 (the “Effective Date”), is entered into by and between ENOCHIAN BIOSCIENCES, INC., a Delaware corporation (the “Company”), and PASECO APS (the “Holder”).
ContractCfo Contract • March 18th, 2015 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations
Agreement between Dandrit Biotech A/S, Fruebjergvej 3, 2100 Kebenhavn 0, CVR 26027322 (Chairman of the board - Attorney at Law Niels Erik Nielsen) and Robert W Wolfe, Randolph, Vermont regarding the continuance and termination of the CFO Contract dated Feb. 10 2014.
SECOND AMENDMENT TO Stock Purchase AgreementStock Purchase Agreement • February 14th, 2024 • Renovaro Inc. • Pharmaceutical preparations
This Second Amendment (this “Amendment”) to the Stock Purchase Agreement, dated as of September 28, 2023 (the “Agreement”), by and among Renovaro Biosciences Inc., a Delaware corporation (“Buyer”), Gedi Cube Intl Ltd., a private limited company incorporated under the laws of England and Wales (“Company”), each of the shareholders of the Company signatory thereto (collectively, the “Sellers”) and Yalla Yalla Ltd., a private limited liability company registered and incorporated under the laws of Malta with company registration number C 103531, in its capacity as representative to the Sellers, is dated February 9, 2024. Capitalized terms used herein, which are not otherwise defined herein, shall have the meanings assigned to such terms in the Agreement.
SUBSCRIPTION AGREEMENTSubscription Agreement • April 3rd, 2023 • Enochian Biosciences Inc • Pharmaceutical preparations • Delaware
